A 35-year-old man with a 6-year history of OCD presents after 12 weeks of sertraline 200 mg daily. He reports that his obsessions (fear of contamination) and compulsions (excessive cleaning, avoidance of public spaces) have shown only a 25% reduction in severity on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). He has tolerated the medication well with no significant side effects. His psychiatrist is considering next steps. Which of the following is the most evidence-based approach for this treatment-resistant OCD?

Explanation

## Definition of Treatment-Resistant OCD **Key Point:** Treatment-resistant OCD is defined as inadequate response (typically <25–35% reduction in Y-BOCS score) after an adequate trial of an SSRI at therapeutic dose for 8–12 weeks. This patient meets criteria: only 25% reduction on sertraline 200 mg after 12 weeks. ## Evidence-Based Management Algorithm for Inadequate Response ```mermaid flowchart TD A["OCD on SSRI 8-12 weeks"]:::outcome --> B{"Y-BOCS reduction ≥35%?"}:::decision B -->|Yes| C["Continue SSRI + CBT/ERP"]:::action B -->|No| D["Step 1: Optimize SSRI dose"]:::action D --> E["Reassess at 4 weeks"]:::decision E -->|Response| C E -->|No response| F["Step 2: Add CBT/ERP"]:::action F --> G["Reassess at 12-16 weeks"]:::decision G -->|Response| C G -->|No response| H["Step 3: Consider augmentation"]:::action H --> I["Add risperidone or aripiprazole"]:::action I --> J["Reassess at 4-6 weeks"]:::decision J -->|Response| C J -->|No response| K["Switch to clomipramine or consider other strategies"]:::action ``` **High-Yield:** The stepwise approach to treatment-resistant OCD is: 1. **Optimize current SSRI** (if not already at max dose) → reassess 4 weeks 2. **Add CBT/ERP** (most robust evidence for combination therapy) → reassess 12–16 weeks 3. **Augment with antipsychotic** (risperidone 2–6 mg/day or aripiprazole 10–15 mg/day) → reassess 4–6 weeks 4. **Switch to clomipramine** (if all above fail) ## Why CBT/ERP Is Essential **Clinical Pearl:** Cognitive-behavioral therapy with exposure and response prevention (ERP) is the gold-standard psychological treatment for OCD. When combined with pharmacotherapy, it yields superior outcomes compared to medication alone. The patient should have been offered CBT/ERP from the start, but if not yet initiated, it is now critical. | Intervention | Evidence | Efficacy | |--------------|----------|----------| | SSRI monotherapy | Strong | 40–60% response rate | | CBT/ERP monotherapy | Strong | 60–80% response rate | | SSRI + CBT/ERP | Very Strong | 70–90% response rate | | SSRI + augmentation (antipsychotic) | Moderate | 50–70% response rate | | Clomipramine | Strong | 50–70% response rate (second-line) | ## Augmentation Strategy **Mnemonic:** **RAA** = Risperidone or Aripiprazole for Augmentation (when SSRI + CBT/ERP insufficient). - **Risperidone:** 2–6 mg/day added to SSRI; evidence base in OCD augmentation. - **Aripiprazole:** 10–15 mg/day; alternative augmentation agent with fewer metabolic effects. - **Timeline:** Reassess after 4–6 weeks of augmentation before considering next step.